pharmaphorum15d
GSK’s Relvar Ellipta comes out on top in real world study
GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...
Frontiers21d
Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
This study aimed to investigate the safety of mepolizumab by analyzing the pharmacovigilance database of the US Food and Drug Administration. Methods: The AE signals associated with mepolizumab from ...
pharmaphorum11y
GSK, Theravance respiratory drug approved for use in Europe
The European Commission has granted marketing authorization to GSK and Theravance's drug, Relvar Ellipta, for use across the 31 European countries. Relvar is a combination of the inhaled ...